| Lin Shen. Gastrointestinal cancer research in the era of precision medicine. Oncol Transl Med, 2017, 3: 1-2. |
| Gastrointestinal cancer research in the era of precision medicine |
| Received:January 24, 2017 Revised:January 24, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:Gastrointestinal cancer research in the era of precision medicine |
| Author Name | Affiliation | E-mail | | Lin Shen | Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China | LIN100@medmail.com.cn |
|
| Hits: 8376 |
| Download times: 9947 |
| Abstract: |
| Lin Shen. M.D., Professor, Chief, Vice President, Peking University
Cancer Hospital. Professor Lin Shen received her degree in oncology from
Peking Medical University and specialized in gastrointestinal cancers. Her
work focuses on precision medicine inadvanced gastric cancer, colorectal
cancer with liver metastases, gastrointestinal stromal tumors, and other
gastrointestinal malignancies. She is also interested in clinical trials and
translational research, especially early stage clinical trials. Professor Shen
has published over 130 papers and has hosted as a principal investigator
or participated in over 80 global and domestic multicenter clinical trials. The
results of several of these studies have provided evidence to standardize
the clinical practice for gastrointestinal tumors in China. Now, Professor
Shen is Chairman of Chinese Anti-cancer Drug Clinical Trials (ACTS),
General Secretary of Gastric Cancer Committee and Vice-chairman of
Colorectal Cancer Committee of Chinese Anti-Cancer Association (CACA),
and also she is Chairman of Chinese Society of Multidisciplinary Team
(CSMDT). |
| Close |
|
|
|